Fetal Pancreatic Stem-Cell Transplant in Patients With Diabetes Mellitus

• Published in: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation Vol. 13 Suppl 3; pp. 160 - 162
• Main Authors: Tuganbekova, Saltanat, Ulyanova, Olga, Taubaldieva, Zhannat, Saparbayev, Samat, Popova, Nadezhda, Kozina, Larissa
• Format: Journal Article
• Language: English
• Published: Turkey 01.11.2015
• Subjects: Adolescent; Adult; Biomarkers - blood; Blood Glucose - metabolism; C-Peptide - blood; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - diagnosis; Diabetes Mellitus, Type 1 - surgery; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - surgery; Female; Fetal Stem Cells - transplantation; Glycated Hemoglobin A - metabolism; Humans; Male; Middle Aged; Pancreas Transplantation - methods; Stem Cell Transplantation - methods; Time Factors; Treatment Outcome; Young Adult
• ISSN: 2146-8427
• DOI: 10.6002/ect.tdtd2015.P89

To determine the efficacy of fetal stem cell transplant for treating patients with diabetes mellitus types 1 and 2. Five patients with diabetes mellitus type 1 and 5 patients with diabetes mellitus type 2 (aged 18-56 years) received a fetal pancreatic stem-cell transplant (cells were 16-18 wk gestation) performed by intravenous infusion at 50 mL/hour. The quantity of fetal stem cells infused was ≥ 5-8*106. We analyzed the patients' C-peptide and glycated hemoglobin levels both before and 3 months after fetal stem cell transplant. In patients with diabetes mellitus type 1, fetal stem-cell transplant led to a significant increase in C-peptide levels, from 0.09 ± 0.01 ng/mL to 0.20 ± 0.07 ng/mL, after 3 months (P < .008). Treatment with fetal pancreatic stem cells may be beneficial for treating patients with type 1 or type 2 diabetes.